> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Wave Life Sciences Plans A Two-Year AATD Trial After FDA Feedback As Quarterly Loss Grows To $61.9 Million
- URL: https://www.bullished.co/wave-life-sciences-plans-a-two-year-aatd-trial-after-fda-feedback-as-quarterly-loss-grows-71591366/
- Published: 2026-10-27T11:40:57.000Z
- Updated: 2026-10-28T16:13:13.000Z
- Description: The biotech says its $431.0 million in cash lasts into the third quarter of 2028, while spending rose from a year earlier.
- Author: Matteo Parrino
- Tags: Earnings, WVE, Industry: Healthcare

[Wave Life Sciences](https://www.bullished.co/tag/wve/), a clinical-stage biotech building RNA medicines, said Tuesday it is [planning a registrational trial](https://www.globenewswire.com/news-release/2026/10/27/3388867/0/en/wave-life-sciences-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) of its RNA-editing drug WVE-006 for alpha-1 antitrypsin deficiency (AATD) after positive FDA feedback, as its third-quarter [net loss widened to $61.9 million](https://www.sec.gov/Archives/edgar/data/0001631574/000119312526432690/d120442dex991.htm?ref=bullished.co) from $53.9 million a year earlier. The company reported the results in an [8-K filed](https://www.sec.gov/Archives/edgar/data/0001631574/000119312526432690/d120442d8k.htm?ref=bullished.co) with its quarterly update.

## A path to accelerated approval

Wave said it is planning a two-year registrational trial of WVE-006 to support potential full approval, with a one-year interim analysis that could support accelerated approval based on AATD biomarkers. The company announced its alignment with the FDA on key aspects of that pathway in October.

The FDA also supports Wave's assay for measuring the mutant and wild-type proteins in the program. CEO Paul Bolno said the plan offers "an efficient path to potential full and accelerated approval, without the need for a separate confirmatory trial."

AATD is a rare inherited disorder that damages the lungs and liver. WVE-006 is one of three lead programs, alongside WVE-007 for obesity and WVE-008 for a genetic form of liver disease.

## Loss widens as spending climbs

The net loss per share was 30 cents, against 32 cents a year earlier, with more shares outstanding. Revenue rose to $13.2 million from $7.6 million.

Research spending reached $53.8 million, up from $45.9 million. General and administrative expenses rose to $25.4 million from $18.1 million.

Cash, cash equivalents and marketable securities [stood at $431.0 million](https://www.globenewswire.com/news-release/2026/10/27/3388867/0/en/wave-life-sciences-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) on September 30, excluding a $12 million GSK milestone due in the fourth quarter. Wave expects that money to fund operations into the third quarter of 2028\. The runway leaves out any future GSK milestone payments.

## GSK deal and the fourth-quarter calendar

GSK, which prepays Wave's costs on their target validation programs, picked a development candidate in September, earning Wave the $12 million milestone. Three more collaboration programs are advancing toward candidate selection. For each program, Wave is eligible for up to $330 million to $375 million in development, launch and commercial milestones, plus tiered royalties on net sales.

In the fourth quarter, Wave expects to start a WVE-007 maintenance trial for patients coming off incretin drugs, file a clinical trial application for WVE-008, and share data from two WVE-006 and WVE-007 cohorts. It also named Monika Vnuk as chief business officer in September.

Wave holds a virtual Research Day on November 4 at 9:30 a.m. ET, with a hepatologist, Arun Sanyal, discussing PNPLA3 liver disease.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Wave Life Sciences, Inc. (WVE)](https://www.sec.gov/Archives/edgar/data/0001631574/000119312526432690/d120442d8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d120442dex991.htm — Wave Life Sciences, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001631574/000119312526432690/d120442dex991.htm?ref=bullished.co) — SEC EDGAR
- [Wave Life Sciences Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/10/27/3388867/0/en/wave-life-sciences-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com

### More on Wave Life Sciences

- [BlackRock Reports 6.8% Passive Stake In Wave Life Sciences, A Stock Down About 81% This Year](https://www.bullished.co/blackrock-reports-6-8-passive-stake-in-wave-life-sciences-a-stock-down-about-81-this-year-7e445b6c/)
- [Wave Will Say This Quarter Whether Obesity Data Comes At Three Months Or Six](https://www.bullished.co/wave-will-say-this-quarter-whether-obesity-data-comes-at-three-months-or-six-7de51565/)
- [Wave Plans One Two-Year Trial To Seek Both Fast-Track And Full Approval Of Its AATD Drug](https://www.bullished.co/wave-plans-one-two-year-trial-to-seek-both-fast-track-and-full-approval-of-its-aatd-drug-65e2b6d7/)

[All Wave Life Sciences (WVE) coverage →](https://www.bullished.co/tag/wve/)